Tuberculosis Testing


With our patented technology we make it possible to detect living pathogens in saliva resulting in easy, precise and cheap Tuberculosis testing – and more lives saved.

Introducing: The world's first non-invasive Tuberculosis test stick

Modern-day Tuberculosis testing has several big drawbacks: it's costly, you need special equipment and it takes days to get the result. On top of that patients often feel very uncomfortable when giving sputum samples. We're here to fix all that.

Our test stick – or lateral flow test – will be:

  • Saving buyers app. 50% of the current price per test
  • Made for Point-Of-Care
  • Detecting Tuberculosis non-invasively via saliva - not sputum
  • Validated through clinical evaluation and field tests
  • CE marked
Our lateral flow test is the result of 25 years of enzyme-activity research.

Our Test Stick Roadmap

Available in 2025, our Tuberculosis lateral flow test will be the first non-invasive Tuberculosis test in the world.

Being able to offer the only saliva-based and non-invasive infectious diseases test stick, we believe that can bite into the multi-billion global Tuberculosis Point-Of-Care market.

But, it’s only the first of an expanding pipeline of diagnostics devices.

Based on our current development, we aim to have our Malaria test stick ready in 2026 or 2027.

The Rolling Circle Amplification Potential

As our technology – Rolling Circle Amplification – detects living organisms, it will be able to detect other infectious diseases resulting in a broad product portfolio.

In theory, Rolling Circle Amplification could detect pathogens in everything from Pox diseases to HIV and Brucella (and many more).

Contact us for more information

We develop high quality Lateral Flow tests that make detection for Tuberculosis easy, accessible and affordable – to improve lives around the world

At VPCIR we believe that we – with our lateral flow tests – can help address the Tuberculosis pandemic and contribute to a healthier and more sustainable world in alignment with the World Health Organization's 2030 goals.

We believe that access to quality healthcare is a fundamental human right. We are committed to developing solutions that are affordable, accessible, and of the highest quality, so that everyone can receive the care they need.

We recognize the global threat of infectious diseases and are dedicated to developing diagnostics devices that can limit the impact from these.

We wish to develop safe and reliable Lateral Flow products of high quality for tuberculosis. To ensure this we are developing our Quality Management System and quality processes towards the requirements stated in ISO 13485:2016 and the EU In Vitro Diagnostic Regulation (IVDR) 2017/746 for later certification.

We acknowledge the critical link between the environment and human health and are dedicated to developing eco-friendly health solutions.

Where we don't have the bandwidth, we will seek like-minded partners.

Our Partners

Patents and Intellectual Property

Diagnosis of Tubercolisis in Saliva

VPCIR™ owns the exclusive global rights to a pending patent on measuring topoisomerase 1 from Mycobacterium tuberculosis complex (MTC) in saliva.

EAN™ Technology for Bacteria Detection

VPCIR™ owns the exclusive global rights to EAN™ Technology – a new way of detecting bacteria using biomarkers called endonucleases. This make them ideal for identifying bacteria like Listeria and Salmonella and many others. Aarhus University holds the patent.

Contact Us

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.